Table 1.
Baseline Characteristics of PLA2R Antibody-Associated MN Patients Treated with Rituximab
| Variables | Training (N=106) | Validation (N=30) | P-value |
|---|---|---|---|
| Gender (male/female) | 82/24 | 24/6 | 0.758 |
| Age (years) | 50.2±12.9 | 54.2±11.4 | 0.129 |
| Time since diagnosis to Rituximab (months) | 24.0 (6.0, 40.0) | 24.0 (5.3, 36.0) | 0.579 |
| BMI (kg/m2) | 25.4±4.1 | 25.1±3.7 | 0.796 |
| BP (mmHg) | |||
| Systolic | 131.8±14.4 | 131.7±13.8 | 0.783 |
| Diastolic | 82.1±9.5 | 82.6±8.2 | 0.981 |
| Pathologic stage of MN [n (%)] | |||
| Stage I | 22 (20.8) | 4 (13.3) | 0.799 |
| Stage I–II | 18 (17.0) | 4 (13.3) | |
| Stage II | 49 (46.2) | 17 (56.7) | |
| Stage II–III | 12 (11.3) | 3 (10.0) | |
| Stage III | 4 (3.8) | 1 (3.3) | |
| Stage IV | 1 (0.9) | 1 (3.3) | |
| Creatinine (µmol/L) | 91.0 (74.0, 132.0) | 86.0 (68.3, 131.0) | 0.836 |
| eGFR (mL/min/1.73m2) | 78.1 (53.1, 103.1) | 81.1 (51.4, 103.7) | 0.836 |
| eGFR >90 [n (%)] | 45 (42.5) | 13 (43.3) | 0.988 |
| eGFR 60–90 [n (%)] | 29 (27.4) | 8 (26.7) | |
| eGFR 30–60 [n (%)] | 23 (21.7) | 7 (23.3) | |
| eGFR 15–30 [n (%)] | 9 (8.5) | 2 (6.7) | |
| Protein-to-creatinine ratio (g/g) | 6.50 (3.98, 9.85) | 6.71 (4.73, 11.68) | 0.239 |
| Albumin (g/L) | 24.1 (19.4, 30.3) | 24.4 (19.1, 30.1) | 0.754 |
| PLA2R antibody titer (RU/mL) | 45.4 (14.8, 110.6) | 54.5 (23.6, 121.9) | 0.589 |
| Patients with immunological remission after previous therapies [n (%)] | 42 (52.5%) | 11 (52.4%) | 0.992 |
| Number (%) of patients with | |||
| Zero round of immunomeds | 26 (24.5) | 9 (30.0) | 0.779 |
| One round of immunomeds | 30 (28.3) | 6 (20.0) | |
| Two rounds of immunomeds | 23 (21.7) | 6 (20.0) | |
| Three rounds of immunomeds | 27 (25.5) | 9 (30.0) |
Note: Data presented as median (first-third interquartile range) or mean ± SD or number (percentage).
Abbreviations: BMI, body mass index; BP, blood pressure; MN, membranous nephropathy; eGFR, estimated glomerular filtration rate; PLA2R antibody, phospholipase A2 receptor antibody.